<span item_type="fundamental" item_id="085b60844604160832c1c29c4de85f1e" counter_id="ST/US/DYCQ" env="prod"></span><span item_type="announcement" item_id="516333768534198273" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.05.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of March 31, 2025, as it is focused on evaluating business combination candidates and will only generate operating revenues after completing a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: For the three months ended March 31, 2025, the company reported a net income of $452,085, compared to $43,875 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li><li><strong>Formation and Operating Costs</strong>: The company incurred formation and operating costs of $288,262 for the three months ended March 31, 2025, compared to $302,382 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the three months ended March 31, 2025, net cash used in operating activities was - $253,559, primarily due to changes in operating assets and liabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: The company reported net cash provided by investing activities of $19,463,396 for the three months ended March 31, 2025, primarily due to cash withdrawn from the Trust Account in connection with redemption.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: The company reported net cash used in financing activities of - $19,361,857 for the three months ended March 31, 2025, primarily due to the redemption of ordinary shares.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Dividend Income</strong>: The company earned dividend income of $740,346 on cash and investments held in the Trust Account for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing a business combination within the extended timeframe, which has been extended to August 23, 2026, if additional funds are deposited into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Business Combination Agreement with Maius Pharmaceutical Co., Ltd., and related entities, with an aggregate consideration of $250,000,000 to be paid in newly issued ordinary shares of Pubco.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li><li><strong>Priority</strong>: The company aims to consummate the business combination within the extended timeframe and has made deposits to extend the Combination Period, indicating a strategic focus on completing the transaction with Maius Pharmaceutical Co., Ltd.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1944212/000164117225010512/form10-q.htm"></span></li></ul>

Dt Cloud Acquisition | 10-Q: FY2025 Q1 EPS: USD 0.05